TEI 2306

Drug Profile

TEI 2306

Alternative Names: Gamma-GCE; Gamma-glutamylcysteine ethyl; γ-GCE; γ-Glutamylcysteine ethyl

Latest Information Update: 17 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Teijin Pharma
  • Class Anti-ischaemics; Ischaemic heart disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV-1 infections; Myocardial ischaemia

Most Recent Events

  • 05 Mar 1999 A preclinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
  • 05 Mar 1999 A preclinical study has been added to the pharmacokinetics section
  • 09 Jul 1998 Preclinical development for HIV-1 infections in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top